PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 28, 2026Cancer Biology & Therapy0 citationsOpen Access

Advances in natural killer cell immunotherapy for hematologic malignancies

View Full Paper
HHHuijie HuNingbo UniversityYXYan XiongNingbo UniversityMXMinxin XiaNingbo University

Key Points

  • This review examines innovations in natural killer cell immunotherapy for treating hematologic malignancies, focusing on effectiveness and future potential.
  • Systematic introduction of NK cell functional mechanisms and subsets
  • Discussion on optimization methods in NK cell therapy
  • Analysis of recent advancements in NK cell infusion techniques
  • Emerging approaches like chimeric antigen receptor NK cells show substantial treatment promise
  • Enhancement strategies improve NK cell expansion efficiency and therapeutic potency
  • NK cell engagers indicate potential for improved cytotoxic efficacy against malignancies

Abstract

Natural killer (NK) cells are a unique subset of cytotoxic lymphocytes within the innate immune system. They play a pivotal role in antiviral and antitumor immunity. NK cell-based adoptive immunotherapy has advanced rapidly in recent years. Innovative approaches, such as autologous/haploidentical NK cell infusion, chimeric antigen receptor NK cells, and NK cell engagers, have emerged, demonstrating promising potential in the treatment of various diseases. Currently, enhancement strategies for NK cell therapy primarily focus on two key aspects: improving expansion efficiency and persistence, with a positive effect on the therapy's potency and cytotoxic efficacy. The present review systematically introduces the functional mechanisms of NK cells and their specialized functional subsets. This review discusses the progress and optimization methods of NK cell therapy and provides an outlook on future research directions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hu et al. (2026) studied this question.

synapsesocial.com/papers/69f04e08727298f751e720a1https://doi.org/10.1080/15384047.2026.2658896
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of a phase I trial with Haploidentical mbIL ‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML2024 · 32 citations
  2. 2High-dimensional single-cell analysis of human natural killer cell heterogeneity2024 · 259 citations
  3. 3The FcγRIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell–Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing2024 · 13 citations
  4. 4An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-cancer Vaccines2024 · 10 citations
  5. 5NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells2006 · 295 citations